Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
EFNS 2012
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
Role of the Blood-Brain Barrier in Multiple Sclerosis.
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
Optimizing IFN Beta - 1B Dose (Optims)
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
Immunomodulatory effects of Vitamin D in multiple sclerosis.
Multiple sclerosis.
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Pages